SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-035108
Filing Date
2023-03-21
Accepted
2023-03-21 16:41:37
Documents
12
Period of Report
2023-03-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310053d5_8k.htm   iXBRL 8-K 31158
  Complete submission text file 0001104659-23-035108.txt   205989

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA casi-20230320.xsd EX-101.SCH 3034
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20230320_lab.xml EX-101.LAB 34477
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20230320_pre.xml EX-101.PRE 22596
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2310053d5_8k_htm.xml XML 3586
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc (DE) (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 23750169
SIC: 2836 Biological Products, (No Diagnostic Substances)